Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT00351169 Completed - Clinical trials for Major Depressive Disorder

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

AMBER
Start date: May 2006
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00335205 Recruiting - Clinical trials for Major Depressive Disorder

A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.

Start date: April 2003
Phase: Phase 4
Study type: Interventional

We hypothesize that depressed patients who have not responded to their current antidepressant medication will respond to the addition of ropinirole to their current regimen at a rate better than placebo.

NCT ID: NCT00332670 Terminated - Clinical trials for Major Depressive Disorder

Light Therapy for Elderly Depression

Start date: January 2003
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to investigate the following two hypotheses: 1. Treatment with bright light improves their sleep, mood, concentration and self-sufficiency of elderly depressed subjects. This clinical improvement is accompanied by decreases in cortisol/DHEA ratio and increases in melatonin concentration in urine and saliva. 2. The eventual beneficial effect of bright light treatment can be predicted by the presence of sleep-wake rhythm disturbances as found using muscle activity registration, and by cortisol/DHEA and melatonin concentrations in saliva and urine over the day and the night.

NCT ID: NCT00331799 Completed - Clinical trials for Major Depressive Disorder

Pilot Study of Duloxetine in Psychological Resilience

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore benefits of duloxetine in enhancing psychological resilience and to understand the relevance of inhibiting of both serotonin (5HT) and norepinephrine (NE)to therapeutic responses.

NCT ID: NCT00326144 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

OPAL
Start date: April 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00326105 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

PEARL
Start date: April 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00321490 Completed - Clinical trials for Major Depressive Disorder

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

DIAMOND
Start date: April 2006
Phase: Phase 3
Study type: Interventional

This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.

NCT ID: NCT00321152 Completed - Clinical trials for Major Depressive Disorder

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

Start date: November 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin®) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).

NCT ID: NCT00320372 Completed - Clinical trials for Major Depressive Disorder

Treatment-Resistant Depression Registry

Start date: January 2006
Phase: N/A
Study type: Observational

This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode. For the purposes of this study, TRD is defined as an ongoing depression lasting at least 2 years or that has recurred at least 3 times, to include the current episode, during the patient's lifetime AND has not adequately responded to 4 or more adequate antidepressive treatments. The registry will follow the clinical course and outcomes for patients with TRD who are treated with and without adjunctive (used along with other treatments for depression) vagus nerve stimulation (VNS) therapy.

NCT ID: NCT00320268 Completed - Clinical trials for Major Depressive Disorder

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder

MOONSTONE
Start date: April 2006
Phase: Phase 3
Study type: Interventional

This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.